Gilead Sciences, Inc.'s Form 4 filing
Xilio Therapeutics, Inc. (XLO) · filed Dec 19, 2024
- Accession no.
- 0001062993-24-020910
- Filed
- Dec 19, 2024
- Trade date
- Dec 18, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 1 derivative transaction. Open-market purchases total $1.83M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gilead Sciences, Inc.CIK 0000882095 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 18, 2024 | Common Stock | PPurchaseAcquired | +1,759,978 | $1.04 | +$1,830,377.12 | 9,105,451 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 18, 2024 | Common Stock | PPurchaseAcquired | +6,092,816 | $1.04 | +$6,336,528.64 | 9,975,266 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.